Participated · Seed · Apr 2026

Illuminant Surgical develops the Skylight platform, which overlays real-time anatomy directly onto a patient to improve procedural precision and streamline workflows. Skylight combines two proprietary technologies: SkinMatch, a non-invasive patient tracking system using adhesive SkinDots and computer vision to align medical images to anatomy in real time; and LightScreen, a depth-adaptive projection system that displays anatomical details on the patient’s skin. The company is led by co-CEOs Dr. James Hu and Eldrick Millares and is based in Los Angeles, CA. Illuminant Surgical recently raised $8.4M in seed funding to accelerate Skylight’s launch. No revenue, user, or prior funding metrics were disclosed in the articles.

Participated · Equity · Jan 2026

Vivere Oncotherapies engineers cancer therapies that activate the immune system to detect and eliminate solid tumors that typically evade immune surveillance. Using a proprietary bioengineering platform created at UC Berkeley, the team designs delivery vehicles that reach tumors more efficiently and release highly selective, immune-stimulating payloads. The company’s scientific approach merges engineering, immunology, and translational expertise to crack the longstanding problem of immunologically cold tumors, which are resistant to conventional checkpoint inhibitors. With its technology, Vivere aims to bring a new generation of targeted and safer immunotherapies to patients who currently have few effective options and poor prognoses. Future plans include advancing these candidates toward clinical development and expanding the platform to additional hard-to-treat cancers. Financially, the company has secured over $10 million in new capital to fuel preclinical development and platform expansion; no other operating metrics or revenue figures were disclosed.

Participated · Grant · Mar 2024

mPATH Health develops a digital cancer‑screening program that integrates automation and behavioral science to drive preventive care. The company says its program has demonstrated the ability to double screening rates across diverse populations regardless of race, ethnicity, income, or literacy level. mPATH plans to expand its screening and preventive health modules and to conduct additional rigorous clinical testing supported by grant funding. The platform emphasizes personalized outreach to identify, educate, and ensure timely access to relevant screenings, with a stated commitment to health equity. The recent funding is intended to accelerate growth, expand reach, and document return on investment for health systems and insurers. mPATH Health integrates automation and behavioral science to improve preventive cancer screening. Led by CEO and Founder Dr. Dave Miller, the company uses plain language, engaging animations, and video testimonials to inform, motivate, and empower individuals to request and complete evidence-based screenings. mPATH is currently in use across three healthcare systems in North Carolina for colorectal and lung cancer screening, and a fourth major healthcare system will launch the program in March. The company raised $1.1M consisting of $706K in angel investments and $400K from a National Cancer Institute Small Business Technology Transfer grant. mPATH plans to use the funds to develop new modules for other preventive care needs, add artificial intelligence to guide its outreach, and accelerate its growth trajectory.

Led · Grant · Oct 2022

Modofi Bio specializes in direct DNA modification to develop therapeutics that target tumor-associated DNA repair defects. The company is based in New Haven, Connecticut, with offices and laboratories at the Elm City Bioscience Center near Yale. It raised an additional $4.3M in seed funding. Investors in this round included existing backers Connecticut Innovation, HighCape Capital, Advantage Capital (Ironwood), and the National Brain Tumor Society, plus new investors Pathway BioVentures, The Sontag Foundation, and BrightEdge (the impact investment arm of the American Cancer Society). Modofi Bio intends to use the funds to advance its lead molecules toward IND-enabling studies and phase I clinical trials. The company’s core approach is exploiting tumor-associated DNA repair defects through direct DNA modification. Modifi Biosciences develops small-molecule therapeutics that directly modify DNA to selectively target tumors with defects in DNA repair, notably loss of MGMT expression. The company’s core platform has been validated in vitro and in vivo in preclinical glioma and other cancer models, showing selective anti-tumor activity and a favorable therapeutic index. Modifi Bio’s lead approach targets cancers lacking MGMT, a defect present in substantial subsets of colon, small cell lung, and non-small cell lung cancers, suggesting broader applicability beyond brain tumors. Founders and scientific leadership include researchers from Yale, and the company is based at the Elm City Bioscience Center in New Haven. The team highlights that their molecules are structurally similar to previously FDA‑tested drugs but are designed to overcome resistance mechanisms. With recent non-dilutive funding and a completed seed round, the company is positioning its assets for IND‑enabling work and first clinical translation.

Participated · Grant · May 2021

miRecule is a pre-clinical biotechnology company that develops RNA therapeutics using its DREAmiR genomics-based discovery platform, created through over a decade of NIH collaboration. The platform integrates genomic and clinical outcomes data to identify RNA targets and design chemically modified RNA therapeutics with targeted delivery. Its lead candidate, MC-30, is being advanced toward clinical development for head & neck cancer, and the company also has MC-DX4, an antisense oligonucleotide program for FSHD. miRecule intends to apply its platform across cancer, muscular dystrophy, and viral indications including HIV and COVID-19. The company spun out of the NIH into BioHealth Innovation’s incubator in 2017 and is based in Gaithersburg, Maryland. miRecule closed over $5.7M in seed funding, including a $2M non-dilutive Phase II SBIR grant from the National Cancer Institute.